文献速递眼整形与眼眶神经眼科

IGF-1R抑制剂IBI311治疗中国活动性甲状腺眼病患者:RESTORE-1随机临床试验

IGF-1R Inhibitor IBI311 for the Treatment of Active Thyroid Eye Disease in Chinese Patients: The RESTORE-1 Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2025-01-01

这项在中国20家三级医院开展的随机、双盲、安慰剂对照、多中心24周3期试验纳入82例活动性(CAS≥3)中重度甲状腺眼病患者,按2:1随机接受IBI311或安慰剂静脉输注。第24周IBI311组突眼缓解率85.8% vs 安慰剂组3.8%(差值81.9个百分点,95%CI 69.8至93.9,P<.001),不良事件均为轻中度,IBI311组无严重不良事件或死亡。

要点

  • 第24周突眼缓解率IBI311组85.8%(45/52)vs 安慰剂组3.8%(1/26),差值81.9个百分点(95%CI 69.8至93.9,P<.001)。
  • 总体应答率80.2% vs 3.6%(差值76.3个百分点,95%CI 63.3至89.4),CAS为0或1者83.5% vs 16.6%(差值67.1个百分点,95%CI 49.4至84.8)。
  • 关注的不良事件(输注反应、听力损害、高血糖、肌肉痉挛、恶心或腹泻)均为轻中度,IBI311组无严重不良事件或死亡。

核心结论

  • IBI311在突眼和CAS方面较安慰剂显示出更好且具有临床相关性的结局,未发现既往临床试验未识别的新安全性问题。
  • 结果提示IBI311是中国活动性甲状腺眼病患者的可行治疗选择。

研究设计与样本

  • 随机、双盲、安慰剂对照、多中心、24周3期试验,2023年5月至12月在中国20家三级医院招募。
  • 纳入活动性(CAS≥3)中重度甲状腺眼病中国患者,排除活动性甲状腺眼病起病超过270天、威胁视力、或曾接受激素冲击、放疗或甲状腺眼病手术者。
  • 82例参与者按2:1随机接受IBI311(n=54)或安慰剂(n=28)静脉输注,每3周一次共21周,随访至第24周。
  • 参与者平均(SD)年龄39.6(10.9)岁,女性56例(68.3%)。

主要发现

  • 第24周突眼缓解(研究眼突眼减少≥2 mm):IBI311组45/52(85.8%)vs 安慰剂组1/26(3.8%),差值81.9个百分点(95%CI 69.8至93.9,P<.001)。
  • 总体应答(突眼减少≥2 mm且CAS减少≥2):IBI311组80.2% vs 安慰剂组3.6%,差值76.3个百分点(95%CI 63.3至89.4)。
  • CAS为0或1:IBI311组83.5% vs 安慰剂组16.6%,差值67.1个百分点(95%CI 49.4至84.8)。
  • 研究眼突眼较基线最小二乘均值(SE)变化:IBI311组-2.85(0.18)mm vs 安慰剂组-0.02(0.24)mm,差值-2.83 mm(95%CI -3.39 mm至-2.27 mm),所有P<.001。
  • 复视应答(复视减少≥1级):IBI311组66.0% vs 安慰剂组53.3%,P=.46。

关键数值与推荐

  • 主要结局为第24周研究眼突眼缓解率(突眼减少≥2 mm)。
  • 所有关注的不良事件(输注反应、听力损害、高血糖、肌肉痉挛、恶心或腹泻)严重程度均为轻中度。
  • IBI311组无严重不良事件或死亡发生。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Thyroid eye disease (TED), a disfiguring and potentially sight-threatening condition with racial phenotypic variations, currently has limited effective treatments. Insulin-like growth factor 1 receptor (IGF-1R) inhibitors therapy has emerged as a promising treatment option, although it remains less accessible and lacks substantial evidence in Asian patients. OBJECTIVE: To assess efficacy and safety of IBI311, an IGF-1R inhibitor with an identical amino acid sequence to teprotumumab but a different dosage form, in Chinese patients with active TED. DESIGN, SETTING, AND PARTICIPANTS: This was a randomized, double-masked, placebo-controlled, multicenter, 24-week phase 3 trial with recruitment conducted across 20 tertiary hospitals in China from May to December 2023. Chinese participants with active (clinical activity score [CAS] ≥3) moderate to severe TED were included after excluding individuals with active TED onset over 270 days; sight-threatening TED; or history of steroid pulse therapy, radiotherapy, or surgery for TED. INTERVENTIONS: Eighty-two participants were randomized 2:1 to receive intravenous infusions of either IBI311 or placebo once every 3 weeks for 21 weeks with follow-up through week 24. MAIN OUTCOMES AND MEASURES: The primary outcome was the proptosis response rate (proptosis reduction ≥2 mm) in the study eye at week 24. RESULTS: Participants (mean [SD] age, 39.6 [10.9] years; 56 [68.3%] women) were randomized to receive IBI311 (n = 54) or placebo (n = 28). At week 24, 45 of 52 participants receiving IBI311 (85.8%) and 1 of 26 receiving placebo (3.8%) had proptosis response (difference, 81.9 percentage points; 95% CI, 69.8 to 93.9; P < .001). The secondary outcomes included overall response (proptosis reduction ≥2 mm and CAS reduction ≥2, 80.2% vs 3.6%; difference, 76.3 percentage points; 95% CI, 63.3 to 89.4), CAS of 0 or 1 (83.5% vs 16.6%; difference, 67.1 percentage points; 95% CI, 49.4 to 84.8), least-squares mean (SE) change from baseline in proptosis (-2.85 [0.18] mm vs -0.02 [0.24] mm; difference, -2.83 mm; 95% CI, -3.39 mm to -2.27 mm) in the study eye (all P < .001), and diplopia response (diplopia reduction ≥1 grade, 66.0% vs 53.3%; P = .46). All adverse events of interest (infusion reaction, hearing impairment, hyperglycemia, muscle spasm, and nausea or diarrhea) were mild or moderate in severity. No serious adverse event or death occurred in the IBI311 group. CONCLUSIONS AND RELEVANCE: In this phase 3 randomized clinical trial, IBI311 demonstrated better and clinically relevant outcomes in proptosis and CAS than placebo with no new safety issues not identified in previous clinical trials. The results suggest that IBI311 represents a viable treatment option for Chinese patients with active TED. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05795621.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Zhang H, Sun J, Li Y, et al. IGF-1R Inhibitor IBI311 for the Treatment of Active Thyroid Eye Disease in Chinese Patients: The RESTORE-1 Randomized Clinical Trial. JAMA Ophthalmol. 2025. PMID: 41066129. doi:10.1001/jamaophthalmol.2025.3350

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。